Global Leukapheresis Market Gaining Momentum—Projected to Reach Worth USD 87.5 Billion in 2027

Published | May 2021

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting revealed that the global leukapheresis market was worth USD 51.6 billion in 2020, and is further projected to reach USD 87.5 billion by 2027, at a CAGR of 7.8% during 2021-2027 (forecast period). The growing number of blood donors worldwide, combined with the growing number of cell-based therapies for the treatment of leukemia, are driving the demand for the global leukapheresis market. Additionally, rising investments by major players in research activities, along with the rising approvals for the process of isolating white blood corpuscles (WBC) for R&D activities are also driving the market growth during the forecast period.

Increasing Number of Blood Cancer Patients Driving Market Growth

Leukemia is a type of blood cancer that develops in the blood and bone marrow. It occurs when the body produces an abnormally large number of white blood cells, interfering with the bone marrow's ability to produce red blood cells and platelets. India is considered a rapidly growing economy that ranks second only to China in terms of population. However, an increase in cancer cases over the last decade has become a major public health issue in this steadily developing nation. Cancer affects a significant number of people in the United States as well. One individual in the United States (US) is diagnosed with blood cancer every three minutes, according to the Leukemia & Lymphoma Society. Leukemia, lymphoma, and myeloma are expected to account for 9.9 % of the estimated 1,806,590 new cancer cases diagnosed in the United States in 2020. It accounts for 34% of all blood cancer cases. The growing number of leukemia patients who need leukapheresis for treatment drives the market growth.

Increasing Number of Blood Donations

An increasing number of blood donors globally has positively impacted the market growth for the global leukapheresis market. Blood transfusions using donated cells from healthy volunteers helps replace red cells, platelets, and other blood components. Patients with leukemia often take chemotherapy medications, which may temporarily impair blood cells and depress the immune system. Blood cancer patients need healthy red blood cells, which can be achieved by blood donation. According to the WHO, 40 % of the 118.5 million blood donations received worldwide are collected in high-income countries, which account for 16 % of the world's population. Furthermore, the increasing number of blood donation camps organized by hospitals, NGOs, research societies, and universities encourages people to donate blood. As a result, the number of blood donors is growing, pushing the market growth even further.

Acute Lymphocytic Leukemia (ALL) Caters the largest share in the Market by Indication

Based on indication, ALL caters to the largest share in the global leukapheresis market. ALL is the most common childhood cancer. It occurs when the DNA of a bone marrow cell becomes faulty. Swollen lymph nodes, bruising, fever, bone pain, gum bleeding, and repeated infections are all possible symptoms. Acute lymphocytic leukemia is the most common form of cancer that affects children and adults. People who have undergone some forms of chemotherapy and radiation therapy for other types of cancer may be at a higher risk of developing acute lymphocytic leukemia. The American Cancer Society predicts that there will be approximately 5,690 new cases of Acute Lymphocytic Leukemia in the United States in 2021 (including both children and adults) and approximately 1,580 deaths from the same.

Impact of COVID-19

Following WHO's declaration of COVID-19 as a pandemic, governments around the world proposed stringent public health initiatives to limit the virus's spread. Cancer research centers, cancer care clinics, and cancer charities have all suffered greatly as a result of stringent policies and a shortage of supplies. As a result of COVID-19, the global leukapheresis market experienced a downfall. Furthermore, restricted access to clinics, combined with social distancing norms, and total lockdown declared by several countries, resulted in a slowdown in patient flow and referral, affecting market development. Cancer screenings dropped dramatically during the COVID-19 outbreak. Repeated cervical cancer screening dropped by 68 % in the first 15 weeks of 2020 in the United States, while breast cancer screening dropped by 17%, with more dramatic drops in areas where the epidemic was strongest.

Global Leukapheresis Market: Regional Insights

Geographically, the global leukapheresis market is categorized into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. The Asia-Pacific region is expected to be the fastest-growing region during the forecast period, owing to an increase in the number of patients, especially in India and China. The growing number of geriatric patients in the area, especially in India, China, and Japan, is driving the expansion. Furthermore, increased healthcare awareness and the increasing demand for early diagnosis of patients in Asia-Pacific, as well as growth in outsourcing activities, drive market growth.

Competitive Landscape

The high growth potential of the leukapheresis market has attracted a host of new entrants, providing a lucrative opportunity. The arrival of new entrants has resulted in more competitive conditions among long-established service providers. Companies like Haemonetics Corporation and Charles River Laboratories are investing in and securing lucrative contracts that will enable humanity to have access to cutting-edge technology in the future.

Some of the key players include Terumo BCT Inc., Lonza Group AG, Puri Blood Medical Co. Ltd, Beijing ZKSK Technology Co. Ltd, Guangzhou Daji Medical Science and Technology Co. Ltd, Miltenyi Biotec, Charles River Laboratories, Caltag Medsystems Limited, Macopharma, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd, Stem Express, LLC, and other prominent players. Companies are rapidly engaging in acquisitions, partnerships, and mergers to boost their production capacity, product range, and competitive differentiation.

In February 2021, Cognate BioServices, a premier cell and gene therapy contract production and manufacturing organization (CDMO), and Cobra Biologics, its gene therapy subsidiary, were acquired by Charles River Laboratories. As a result of the proposed acquisition, Charles River will become a leading science partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution.

Don’t miss the business opportunity of the global leukapheresis market. Consult our analysts to gain crucial insights and facilitate your business growth.

 

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the global leukapheresis market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the ­­­leukapheresis market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

 

 

About Us

 

BlueWeave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.